Comparative Pharmacology

Head-to-head clinical analysis: CYCLACILLIN versus NITROFURANTOIN MACROCRYSTALLINE.

Peer-Reviewed Evidence

Differential Analysis

CYCLACILLIN vs NITROFURANTOIN MACROCRYSTALLINE

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

CYCLACILLIN

Antibiotic

Category C

NITROFURANTOIN MACROCRYSTALLINE

Antibiotic

Category D/X

Head-to-Head

Clinical Matrix

Mechanism of Action

Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.

Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit multiple bacterial enzymes involved in carbohydrate metabolism, including acetyl-CoA synthetase, and disrupt cell wall synthesis.

Clinical Dosing

250-500 mg orally every 6 hours.

100 mg orally twice daily for 5-7 days (uncomplicated UTI); 100 mg orally every 12 hours for 10-14 days (pyelonephritis: not first-line).

Direct Interaction

None Documented

Half-Life

0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.

Other Significant Interactions

Clinical Note

moderate

Cyclacillin + Probenecid

"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."

Clinical Note

moderate

Cyclacillin + Mycophenolic acid

"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy."

Clinical Note

moderate

Cyclacillin + Plicamycin

"The serum concentration of Plicamycin can be decreased when it is combined with Cyclacillin."

Clinical Note

moderate